Print   

Thursday 20 November, 2008

Akers Biosciences

U.S. Over-the-Counter Distrib

RNS Number : 5305I
Akers Biosciences, Inc.
20 November 2008
 

Embargoed: 0700hrs20 November 2008


Akers Biosciences Inc.

('ABI' or the 'Company')


ABI Signs Multi Product Over-the-Counter Distribution Agreement


Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that it has signed an agreement with a large U.S. distributor specialising in over-the-counter diagnostic products. The distributor, who cannot be named for commercial reasons, will market several of the Company's products to the U.S. retail market, including Tri-Cholesterol, the only disposable, rapid test in the world to read HDL, LDL and Total cholesterol levels.


Marketing of ABI's products under the agreement will begin immediately to drug, food and convenience stores and  mass retailers. Clients include such retailers as Kmart, Wal-Mart, CVS, Walgreens, 7-Eleven, Safeway, Costco  and Target.


Currently ABI has limited representation in the U.S. retail markets for over-the-counter sales but this agreement  will transform the scale of personnel marketing ABI's products and the regions in which the Company is able to penetrate.

Thomas NicolettePresident and Chief Executive Officer of ABI said,

'This agreement represents a significant step in our strategy to penetrate a large segment of the U.S.  retail healthcare market to complement our aggressive activities in the hospital and clinical laboratory arenas. There is a clear need for many of our products for use directly by consumers and we are pleased to partner with distributors who have the networks and ability to take our tests to them.'



Enquiries:


Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

    

Ben Simons
M: Communications
Tel. +44 (0)20 7153 1540


Alasdair Younie

Arbuthnot Securities Limited

Tel. +44 (0)20 7012 2000

About Akers Biosciences

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRUKABRWSRAAAA

Investegate takes no responsibility for the accuracy of the information within the site.


The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.



Investegate      © 2012 FE. All rights reserved.